Prof. Filiz Onat, Principal Investigator of the GEMSTONE Project, represented Acibadem Mehmet Ali Aydinlar University (ACU) at The Synuclein Meeting 2025 held at the University of Cambridge from 8 to 11 April 2025.
The prestigious event brought together global experts to discuss the structure, physiology, and pathology of alpha-synuclein, as well as advances in biomarkers and therapeutic strategies for alpha-synucleinopathies.
Prof. Onat delivered a poster presentation titled “Investigation of alpha-synuclein levels in an animal model of absence epilepsy”, showcasing GEMSTONE’s interdisciplinary research on neurodevelopmental aspects of brain disorders. The study – conducted in collaboration with Talat Taygun Turan, Merve Cavus, and Nursima Mutlu – represents the first investigation of alpha-synuclein levels in absence epilepsy using the GAERS (Genetic Absence Epilepsy Rats from Strasbourg) animal model.
Using ELISA-based quantification, the team measured alpha-synuclein concentrations in both brain and plasma samples of GAERS and Wistar control rats. Their findings revealed sex-based differences in brain alpha-synuclein levels among control animals, but no significant differences across sexes in GAERS rats or in plasma levels between groups.
The conference setting offered a rich platform for scientific exchange, with sessions spanning from fundamental discoveries to translational applications in neurodegenerative diseases. Highlights included vibrant discussions on biomarker development and therapeutic innovations, culminating in a gala dinner at the iconic King’s College – fostering valuable networking and collaboration opportunities.
Prof. Onat’s participation underscores the GEMSTONE Project’s commitment to advancing neuroscience research and strengthening ACU’s visibility in the international scientific community.